Hui Jin, MD

Research fellow
the First Affiliated Hospital with Nanjing Medical University, China (People's Republic)

Poster(s):

• 1204 - EGR2 Hotspot Mutations Drive BTKi Resistance in Chronic Lymphocytic Leukemia via CD27-CD70 Interaction-Mediated T-Cell Exhaustion

• 1429 - Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)